Vianautis

Targeted Nanomedicines

General Information
Company Name
Vianautis
Founded Year
2018
Location (Offices)
Cambridge, United Kingdom +1
Founders / Decision Makers
Number of Employees
42
Industries
Biopharma, Biotechnology
Funding Stage
Series A
Social Media

Vianautis - Company Profile

ViaNautis, formerly known as SomaServe, was founded in 2018 as a spin-off from UCL under the leadership of CEO and serial entrepreneur, Dr Francesca Crawford. The company’s core mission is to exploit the unique capabilities of the revolutionary polyNaut® technology.

PolyNaut® is a versatile nano-engineered polymer technology designed for targeted intracellular delivery. This innovative technology enables polymer nanoparticles to deliver a wide range of payloads from small molecules to genetic materials creating ‘a bionic nanoparticle.’ The highly adaptable polymer structure of polyNaut® can be formulated to encapsulate a wide array of genetic cargoes, with sizes exceeding current standards for viral and non-viral delivery. Notably, it enhances the therapeutic efficacy of encapsulated molecules through direct delivery to the cell cytoplasm, facilitated by GOTO® technology for intracellular shuttling.

PolyNaut® is set apart from conventional non-viral delivery technologies through its remarkable ability to target specific cells and penetrate biological barriers, including the challenging blood-brain barrier. PolyNaut® nanoparticles, when functionalised for CNS delivery through transcytosis, exhibit exceptional brain uptake.

Deploying its state-of-the-art polyNaut® platform, ViaNautis is at the forefront of pioneering new therapies for CNS diseases and cystic fibrosis. The company is actively building an internal pipeline and collaborating with leading pharmaceutical and biotech companies to unlock the potential of promising genetic molecules as well as new therapeutic platforms.

The company received a £20.00M Series A investment at 13 November 2023 from 4BIO Capital, BGF, Cystic Fibrosis Foundation, Eli Lilly, UCB Ventures, Origin Capital, o2h Ventures, Meltwind Advisory.

Taxonomy: Nanomedicine, Drug delivery technology, Intracellular delivery, Genetic therapies, Polymer nanoparticle technology, Blood-brain barrier crossing, Central nervous system diseases, Cystic fibrosis therapies, Pharmaceutical collaborations, Biotech partnerships

Funding Rounds & Investors of Vianautis (3)

View All
Funding Stage Amount No. Investors Investors Date
Series A £20.00M 8 Meltwind Advisory 13 Nov 2023
Series A £2.10M 2 Abcam 20 Apr 2021
Seed Round Unknown - 15 Jul 2019

Latest News of Vianautis

View All

No recent news or press coverage available for Vianautis.

Similar Companies to Vianautis

View All
GenEdit - Similar company to Vianautis
GenEdit Delivering the potential of genetic medicines
Nanite - Similar company to Vianautis
Nanite Deliver the Undeliverable
Trince - Similar company to Vianautis
Trince Precision Transfections
Trince - Similar company to Vianautis
Trince Precision Transfections
Aliada Therapeutics - Similar company to Vianautis
Aliada Therapeutics Beyond boundaries: Crossing the blood-brain barrier to create the next generation of central nervous system therapies